Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

NCT07235306 | Not Yet Recruiting Phase 2

• 1 other identifier: L25-616
• Study Type: interventional
• Target: 45
• Locations: 0 countries
• Sites: N/A

Brief Summary

The PACIFIC study established the standard of care for immunotherapy consolidation after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). However, its benefit is limited in patients with driver gene mutations. The LAURA study established a new paradigm of targeted consolidation therapy after CRT for patients with EGFR mutations. Although retrospective data support the efficacy of ALK-TKIs, no randomized controlled trial (RCT) has clearly demonstrated the value of ALK-TKI maintenance therapy after CRT. This study adopts a multicenter, randomized, double-blind, placebo-controlled design aimed at evaluating the efficacy and safety of ensartinib in patients with ALK-positive unresectable stage III NSCLC.

Conditions

NSCLC Stage III; Ensartinib; Chemoradiotherapy; ALK

Outcome Measures

Primary Outcomes (1)

• progressive free survival

  disease progression according to RSCIST v1.1 or intolerable toxicity according to CTCAE v5.0

  From enrollment to the end of treatment, up to 100 months

Secondary Outcomes (5)

• Objective Response Rate

  From first dose of study drug until disease progression, assessed up to approximately 12 months

• Disease Control Rate

  From first dose of study drug until disease progression, assessed up to approximately 12 months

• Overall Survival (OS)

  From randomization until death from any cause, up to 120 months

• Central Nervous System Progression-Free Survival (CNS-PFS)

  From randomization until CNS progression or death, up to 100 months

• Incidence of Adverse Events (AEs)

  Approximately up to 100 months

Other Outcomes (1)

• Exploratory Analysis of Biomarkers and Efficacy

  Blood samples will be collected at the following time points: before chemoradiotherapy, within 6 weeks after chemoradiotherapy, at 6 months of medication, and through study completion, an average of 5 year

Study Arms (2)

Ensartinib

EXPERIMENTAL

Ensartinib (225mg orally, once daily), in accordance with the randomization schedule

Drug: Ensartinib 225mg

Placebo Ensartinib

PLACEBO COMPARATOR

Matching placebo for Ensartinib (225mg orally, once daily), in accordance with the randomization schedule

Drug: Placebo Ensartinib 225mg

Interventions

Ensartinib 225mg DRUG

225mg once daily, until disease progression, unacceptable toxicity or other discontinuation criteria are met

Ensartinib

Placebo Ensartinib 225mg DRUG

225mg once daily, until disease progression, unacceptable toxicity or other discontinuation criteria are met

Placebo Ensartinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged at least 18 years
• Histologically or cytologically confirmed Stage III unresectable non-small cell lung cancer (NSCLC) with curative treatment intent
• ALK mutations assessed by FISH, IHC, or NGS
• ECOG Performance Status of 0 or 1
• Completion of platinum-based concurrent or sequential chemoradiotherapy as per protocol requirements
• Chemoradiotherapy must have been completed ≤ 6 weeks prior to randomization
• No disease progression during or after chemoradiotherapy
• Life expectancy \> 12 weeks
• Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment
• Signed informed consent form obtained from the patient or their legally authorized representative
• Male and female patients of childbearing potential agree to use highly effective contraception methods from before entering the trial, throughout the study, and until 8 weeks after discontinuation of study treatment

You may not qualify if:

• Mixed histology of small cell and non-small cell lung cancer
• Symptomatic pneumonitis following chemoradiotherapy that has not resolved to ≤ Grade 1 (per CTCAE criteria) prior to randomization;
• Any unresolved toxicity from prior chemoradiotherapy with toxicity ≥ Grade 2 (according to CTCAE criteria);
• Poor cardiac function, including but not limited to any of the following:
• Mean resting corrected QT interval (QTc) \> 470 msec (obtained from 3 ECGs);
• Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG;
• Any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or concomitant use of any known drugs that prolong the QT interval and may lead to Torsades de Pointes;
• Inadequate bone marrow reserve or organ function;
• History of other malignant malignancies, except for adequately treated non-melanoma skin cancer or malignant lentigo, cured carcinoma in situ, or other solid tumors cured \> 5 years ago with no evidence of disease and considered by the treating physician to have a low risk of recurrence;
• Severe or uncontrolled systemic diseases: including uncontrolled hypertension and active bleeding tendency; or active infections, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);
• Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of ensartinib;
• Any prior chemotherapy, radiotherapy, immunotherapy, or investigational drug therapy beyond the definitive treatment for locally advanced disease;
• Prior treatment with any ALK tyrosine kinase inhibitor (ALK-TKI);
• Major surgery within 4 weeks prior to the first dose of study drug;
• Current use of medications known to be strong inducers of CYP3A4 (which cannot be discontinued at least 3 weeks prior to the first dose of study drug);

Sponsors & Collaborators

• Shanghai Pulmonary Hospital, Shanghai, China: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

ensartinib

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: chiefphysician

Study Record Dates

• First Submitted: September 23, 2025
• First Posted: November 19, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): January 31, 2031
• Study Completion (Estimated): December 31, 2031
• Last Updated: November 19, 2025

Record last verified: 2025-07